Global Cholera Vaccine Market Size Likely to Grow at a CAGR of 7.6% By 2035

The market size of the global cholera vaccine will be estimated at USD 312 million in 2025 and is expected to grow between USD 336 million in 2026 and about USD 649 million by 2035 with a current CAGR of 7.6% during the period of 2026 to 2035.

Cholera Vaccine Market Revenue and Trends

A cholera vaccine is an organism that makes qualities of biological origin, which are preventive and one of the main characteristics is that they are meant to protect people from cholera, a disease of the bowel where the causative agent is the cholera bacterium Vibrio cholerae, mainly through water and food that are not clean. Currently, the majority of cholera vaccines are oral ones that have either killed whole cells of Vibrio cholerae or a mixture of killed cells and the recombinant cholera toxin B-subunit, thus effectively activating the immune response in the gut, leading to the production of protective antibodies that last for a while but not too long.

That is why these vaccines are mostly utilized to prevent cholera outbreaks in endemic areas, manage epidemics during crises, and safeguard the travelers and people with high-risk occupations. The World Health Organization and other global health authorities back up this vaccination, and thus it has become an indispensable part of the public health system, as it is through the vaccine that less disease severity, transmission, and mortality take place, particularly in places where access to water and sanitation is very limited.

What are the Factors That Have a Significant Contribution to the Growth of the Cholera Vaccine market?

Supportive government regulations and public health programs are the main factors of the cholera vaccine market as the authorities from the national and international levels are recognizing more and more the vaccination as the main thing to be done for preventing the disease and controlling the outbreaks. The governments of countries where cholera is endemic have started to include the oral cholera vaccines in the routine immunization and emergency preparedness plans thus allowing for large-scale stockpiling and regular distribution during outbreaks.

The support of the World Health Organization, Gavi, the Vaccine Alliance, and UNICEF has been a major factor in the market growth through the provision of funds, subsidies for vaccines, and the global management of cholera vaccine stockpiles. All these efforts are aimed at making vaccines accessible and reachable in low and middle-income countries by cutting down on their financial and logistical barriers. Moreover, government-driven public health campaigns and surveillance programs are not only improving outbreak preparedness but also ensuring that there is continual demand for cholera vaccines. Altogether, supportive policies and coordinated public health actions are making a stable and predictable procurement environment, which, in turn, is directly driving the growth of the cholera vaccine market.

Segment Insight

By Product

The dukoral segment is growing at a significant rate over the projected period. The expansion is mainly backed by its effective preventive and travel vaccinations over mass outbreaks on other occasions. Dukoral—a vaccine for cholera—has been composed of the dead bacterium Vibrio cholerae O1 and a recombinant B-subunit. It is given mostly to people who are traveling internationally, aid workers, and people living near or going to see cholera-endemic areas. This group of patients is huge and the patients are spread through hospitals, retail pharmacies, and travel clinics, especially in Europe and North America. Dukoral benefits from its long-standing market presence, safety record accepted by the regulators and WHO recommendations, which gives a lot of confidence to patients as well as to the doctors.

Regional Insights

The cholera vaccine market has been dominated by North America. The existence of vigorous research and development undertakings and the involvement of leading pharmaceutical firms in cholera vaccine production and distribution boost the performance of the regional market even more.

Besides, the Asia Pacific market has the highest rate of growth in the cholera vaccine market. The key factor is the location of the local vaccine companies and the increase in production capacity in Asia Pacific. Bharat Biotech, Biological E., and EuBiologics are the companies that are working in India, South Korea, and other countries around there, which will make the oral cholera vaccines more accessible and cheaper in the region and also improve the reliability of the supply chains.

Report Scope

Recent Developments

• In April 2024, Gavi, the Vaccine Alliance and UNICEF expressed their satisfaction with the announcement that a completely new oral cholera vaccine (OCV), Euvichol-S, has gotten WHO prequalification and is thereby able to be supplied to all countries. The prequalification of this new product will allow EuBiologics, the manufacturer, to produce larger quantities of vaccine quicker and more economically – this is a crucial step in increasing supply while cholera outbreaks are occurring globally at an unprecedented rate. (Source: https://www.unicef.org/press-releases/gavi-and-unicef-welcome-approval-new-oral-cholera-vaccine)

List of the prominent players in the Cholera Vaccine Market:

• Sanofi S.A.

• Hilleman Laboratories

• Biological E.

• Celldex Therapeutics

• EuBiologics

• GlaxoSmithKline

• Bharat Biotech

• Pfizer

• Bavarian Nordic A/S

• Shanghai United Cell Biotechnology Co. Ltd.

• Shantha Biotechnics

• Valneva Sweden AB

• Others

The Cholera Vaccine Market is segmented as follows:

By Type

• Whole Cell v. Cholerae O1 with Recombinant B- subunit

• Killed Oral O1 and O139

By Product

• Vaxchora

• Shanchol

• Dukoral

• Others

By Distribution Channel

• Retail Pharmacy

• Hospital Pharmacy

• Others

Regional Coverage:

North America

• U.S.

• Canada

• Mexico

• Rest of North America 

Europe

• Germany

• France

• U.K.

• Russia

• Italy

• Spain

• Netherlands

• Rest of Europe

Asia Pacific

• China

• Japan

• India

• New Zealand

• Australia

• South Korea

• Taiwan

• Rest of Asia Pacific 

The Middle East & Africa

• Saudi Arabia

• UAE

• Egypt

• Kuwait

• South Africa

• Rest of the Middle East & Africa

Latin America

• Brazil

• Argentina

• Rest of Latin America